BioSpace News Archive

Clopidogrel is an antiplatelet agent of thienopyridine, which is primarily used to prevent the blood clots and help against cardiovascular problems associated with the blood clotting.

Oyster Point Pharma, Inc., announced that the U.S. Food and Drug Administration has approved TYRVAYA™ Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the launch of the Spatial Organ Atlas, an annotated reference dataset of spatially resolved whole transcriptomes, providing a foundational knowledge base for researchers to quickly discover how organs function in both healthy and disease states, using the GeoMx® Digital Spatial Profiler.

VisualDx, a global leader in web-based clinical decision support, announced that it has entered into an agreement with Janssen Biotech, Inc., one of the pharmaceutical companies of Johnson & Johnson.

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced the appointment of Dale Levitzke as Senior Vice President Global Sales and Support.

Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced installation of its Genesis Robotic Magnetic Navigation system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment of cardiac arrhythmias.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors.

Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced the completion of an Investigator Pre-Investigational New Drug process following receipt of written comments from the U.S.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, “Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models” at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021.

Blade Therapeutics, Inc. (Blade or the company), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the initiation of a phase 1 drug-drug interaction clinical study of cudetaxestat.